Analysis of risk factors in breast cancer patients with hand-foot syndrome and oral mucositis caused by pegylated liposomal doxorubicin

IntroductionDoxorubicin (DOX) is a primary treatment for breast cancer (BC), but its widespread use is hindered by cardiotoxicity. Pegylated liposomal doxorubicin (PLD) has been developed to enhance the efficacy of DOX and mitigate its cardiotoxic effects. However, PLD is associated with adverse rea...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Xianghua Quan, Jing Li, Jialin Sun, Xiaomin Xing, Donghua Liu, Hongyan Ji, Qie Guo
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Subjects:	adverse reactions breast cancer pegylated liposomal doxorubicin hand-foot syndrome oral mucositis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1564681/full